Mol Biol Cell. 2011 Jun 1;22(11):1807-9. doi: 10.1091/mbc.E11-03-0187.
Academia should be willing to shoulder some of the responsibility for the current dearth of new therapeutic drugs. Our research funding is predicated on the assumption that it will bring value to society, but our emphasis on scientific specialization hinders our ability to add value when a broader vision is required. A solution is the creation of an academy of science generalists motivated to bring together clinical and basic scientists, academia and the private sector, government legislators and industry. A small investment in academic generalists could yield benefits far beyond its modest cost.
学术界应该愿意为当前新治疗药物的匮乏承担部分责任。我们的研究资金是基于这样一种假设，即它将为社会带来价值，但当需要更广阔的视野时，我们对科学专业化的强调却阻碍了我们增加价值的能力。解决办法是创建一个由科学通才组成的科学院，他们的动机是将临床和基础科学家、学术界和私营部门、政府立法者和工业界聚集在一起。在学术通才方面的少量投资可能会带来远远超出其适度成本的收益。
